The current status of toxicity protectants in cancer therapy.
Current therapies for the treatment of malignancies are associated with significant toxicity, as chemotherapy and radiation therapy do not discriminate between normal and malignant cells. One approach to ameliorating the toxicity associated with therapy is through the use of chemoprotective agents. This article reviews a variety of agents that have been evaluated as possible protectants, including WR-2721 and the colony-stimulating factors. It is hoped that the understanding of how to optimally use chemoprotective agents will lead to more tolerable treatments for patients, and possibly allow for dose-escalation, which may contribute to improvement in patient survival.
Schuchter
L M
LM
Hematology/Oncology Section, Hospital of the University of Pennsylvania, Philadelphia, PA 19104.
Luginbuhl
W E
WE
Meropol
N J
NJ
D004999:Amifostine / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000037:antagonists & inhibitors*; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000627:therapeutic use; D004050:Ditiocarb / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D011837:Radiation-Protective Agents / Q000494:pharmacology / Q000627:therapeutic use
D000970:Antineoplastic Agents; D016207:Cytokines; D011837:Radiation-Protective Agents; D004050:Ditiocarb; D004999:Amifostine